Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities.

Immunotherapy

Department of Research Oncology, King's College London, Guy's Hospital Campus, Great Maze Pond, London, SE1 9RT, UK.

Published: June 2017

Chimeric antigen receptor T-cell therapy has achieved highly promising results in clinical trials, particularly in B-cell malignancies. However, reports of serious adverse events including a number of patient deaths have raised concerns about safety of this treatment. Presently available preclinical models are not designed for predicting toxicities seen in human patients. Besides choosing the right animal model, careful considerations must be taken in chimeric antigen receptor T-cell design and the amount of T cells infused. The development of more sophisticated in vitro models and humanized mouse models for preclinical modeling and toxicity tests will help us to improve the design of clinical trials in cancer immunotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.2217/imt-2017-0028DOI Listing

Publication Analysis

Top Keywords

chimeric antigen
12
antigen receptor
12
preclinical models
8
predicting toxicities
8
receptor t-cell
8
clinical trials
8
receptor cells
4
cells treatment
4
treatment cancer
4
cancer future
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!